The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has directed Zydus ...

In a meta-analysis, both the 200-mg and 400-mg doses were effective, although the 400-mg dose was more effective in those ...

This study from Kerman University of Medical Sciences have that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) ...

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.

Adults with T2D were randomly assigned to receive 3, 7, or 14 mg oral semaglutide, placebo, 25 mg empagliflozin, 100 mg sitagliptin, or 1.8 mg liraglutide. [O]ral semaglutide 14 mg (or flexible dosing ...

Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for ...

Treatment of heart failure (HF) with the SGLT2 inhibitor empagliflozin was accompanied by further activation of the erythropoietin-erythroferrone-transferrin-receptor-protein-1 (TfR1)-hepcidin axis, ...

Although empagliflozin was shown to profoundly reduce cardiovascular events in diabetic patients and blunt the decline in cardiac function in nondiabetic mice with established heart failure (HF), the ...

Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction.